BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17382246)

  • 21. Lack of B cells precursors in marrow transplant recipients with chronic graft-versus-host disease.
    Storek J; Witherspoon RP; Webb D; Storb R
    Am J Hematol; 1996 Jun; 52(2):82-9. PubMed ID: 8638646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential analysis of HLA-C-specific killer cell inhibitory receptor (CD158b) expressing peripheral blood mononuclear cells during chronic graft-versus-host disease.
    Tanaka J; Tutumi Y; Mori A; Ohta S; Kobayashi S; Asaka M; Imamura M
    Bone Marrow Transplant; 2000 Aug; 26(3):287-90. PubMed ID: 10967567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cathepsins are required for Toll-like receptor 9 responses.
    Matsumoto F; Saitoh S; Fukui R; Kobayashi T; Tanimura N; Konno K; Kusumoto Y; Akashi-Takamura S; Miyake K
    Biochem Biophys Res Commun; 2008 Mar; 367(3):693-9. PubMed ID: 18166152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation.
    Iori AP; Torelli GF; De Propris MS; Milano F; Pupella S; Gozzer M; Mancini F; Milani ML; Intoppa S; Cerretti R; Lucarelli B; Valle V; Malandruccolo L; Iannella E; Arleo E; Guarini A; Foà R
    Transplantation; 2008 Feb; 85(3):386-90. PubMed ID: 18322430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasmacytoid dendritic cell count on day 28 in HLA-matched related allogeneic peripheral blood stem cell transplant predicts the incidence of acute and chronic GVHD.
    Rajasekar R; Mathews V; Lakshmi KM; Sellathamby S; George B; Viswabandya A; Daniel D; Chandy M; Srivastava A
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):344-50. PubMed ID: 18275901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse.
    Yakoub-Agha I; Saule P; Magro L; Cracco P; Duhamel A; Coiteux V; Bruno B; Dufossé F; Jouet JP; Dessaint JP; Labalette M
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):496-504. PubMed ID: 19285638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical evaluation of oral chronic graft-versus-host disease.
    Treister NS; Cook EF; Antin J; Lee SJ; Soiffer R; Woo SB
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):110-5. PubMed ID: 18158967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset.
    Bohmann EM; Fehn U; Holler B; Weber D; Holler E; Herr W; Hoffmann P; Edinger M; Wolff D
    Ann Hematol; 2017 Feb; 96(2):299-310. PubMed ID: 27942862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical analysis of late-onset nephrotic syndrome after allogenic hematopoietic stem cell transplantation].
    Luo XD; Liu QF; Ning J; Wei YQ; Fan ZP; Zhang Y; Sun J
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(46):3280-3. PubMed ID: 18396625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
    Giebel S; Nowak I; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Holowiecki J; Holowiecka-Goral A; Markiewicz M; Kopera M; Karolczyk A; Kyrcz-Krzemien S; Kusnierczyk P
    Eur J Haematol; 2009 Oct; 83(4):343-56. PubMed ID: 19500138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potentiation of TLR9 responses for human naïve B-cell growth through RP105 signaling.
    Yamazaki K; Yamazaki T; Taki S; Miyake K; Hayashi T; Ochs HD; Agematsu K
    Clin Immunol; 2010 Apr; 135(1):125-36. PubMed ID: 20133206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isomorphic cutaneous graft-versus-host disease reaction after ultraviolet exposure: clinical, histological and direct immunofluorescence studies of four allo-transplanted patients.
    Vassallo C; Brazzelli V; Zecca M; Locatelli F; Alessandrino PE; Borroni G
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):913-8. PubMed ID: 19586515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease.
    Lee S; Cho BS; Kim SY; Choi SM; Lee DG; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Shin WS; Kim CC
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1083-94. PubMed ID: 17697971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New classification of chronic GVHD: added clarity from the consensus diagnoses.
    Arora M; Nagaraj S; Witte J; DeFor TE; MacMillan M; Burns LJ; Weisdorf DJ
    Bone Marrow Transplant; 2009 Jan; 43(2):149-53. PubMed ID: 18794869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
    Ratanatharathorn V; Pavletic S; Uberti JP
    Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
    Jurado M; Vallejo C; Pérez-Simón JA; Brunet S; Ferra C; Balsalobre P; Pérez-Oteyza J; Espigado I; Romero A; Caballero D; Sierra J; Ribera JM; Díez JL
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):701-6. PubMed ID: 17531780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and igm memory B cells.
    D'Orsogna LJ; Wright MP; Krueger RG; McKinnon EJ; Buffery SI; Witt CS; Staples N; Loh R; Cannell PK; Christiansen FT; French MA
    Biol Blood Marrow Transplant; 2009 Jul; 15(7):795-803. PubMed ID: 19539210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria.
    Jagasia M; Giglia J; Chinratanalab W; Dixon S; Chen H; Frangoul H; Engelhardt B; Goodman S; Greer J; Kassim A; Morgan D; Ruffner K; Schuening F
    Biol Blood Marrow Transplant; 2007 Oct; 13(10):1207-15. PubMed ID: 17889358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.